SOPHiA GENETICS has launched the residual acute myeloid (RAM) Application to its SOPHiA DDM platform. The new solution strengthens the company's oncology portfolio with measurable residual disease (MRD) testing capabilities.
The RAM Application uses next-generation sequencing (NGS) technology, for post-remission monitoring and identifying early relapse in acute myeloid leukemia (AML) patients. This application leverages the analytical capabilities of the SOPHiA DDM Platform. It is claimed to enable sensitive variant detection down to 0.01% VAF, covering guideline-recommended genes to deliver insights for residual acute myeloid. The solution also offers customizable reporting features and comprehensive MRD reports and leverages machine learning for accurate results within four days.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.